Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded down 1.6% on Tuesday . The company traded as low as $5.72 and last traded at $5.75. 2,857,604 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 12,252,407 shares. The stock had previously closed at $5.84.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners cut their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and a consensus price target of $8.20.
View Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Price Performance
The stock has a 50-day simple moving average of $5.82 and a 200 day simple moving average of $6.74. The company has a market cap of $2.29 billion, a PE ratio of -3.73 and a beta of 1.00. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same quarter last year, the firm posted ($0.42) earnings per share. The firm's quarterly revenue was down 57.8% on a year-over-year basis. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Institutional Trading of Recursion Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in RXRX. Softbank Group CORP. purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth $99,152,000. Novo Holdings A S acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth about $68,375,000. Vanguard Group Inc. grew its position in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $23,429,000. Finally, Laurion Capital Management LP purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $16,611,000. Institutional investors and hedge funds own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.